Sunshine Biopharma Inc. (SBFM) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Sunshine Biopharma Inc. is a pharmaceutical company operating primarily through two Canadian subsidiaries: Nora Pharma Inc. (generic prescription drugs) and Sunshine Biopharma Canada Inc. (OTC supplements). The company operates as a single segment, focusing on the Canadian generic drug market and proprietary drug development (oncology and antivirals). As of May 13, 2026, there were 5,005,945 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Sales (Revenue) | $8,088,765 | $8,901,341 |
| Gross Profit | $2,180,990 (27.0% margin) | $2,730,426 (30.7% margin) |
| Operating Loss | $(1,395,597) | $(1,295,750) |
| Net Loss | $(1,243,869) | $(1,179,771) |
| Diluted EPS (Basic) | $(0.25) | $(0.44) |
| Cash and Equivalents (End of Period) | $6,913,013 | $8,124,610 |
| Net Cash Used in Operating Activities | $(2,072,100) | $(1,695,002) |
| Total Assets | $27,930,375 | $30,079,167 |
| Total Liabilities | $6,413,781 | $7,040,707 |
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased by 9.1% ($812,576) primarily due to the termination of distribution agreements effective December 31, 2025, reducing the active drug portfolio from 71 to 60 products.
- Gross Margin Compression: Gross margin decreased from 30.7% to 27.0% as cost of sales remained relatively high compared to the reduced revenue base.
- Expense Reductions: General & Administrative expenses decreased by $449,589 (11.2%), driven by significant reductions in consulting fees ($222k), accounting fees ($118k), and R&D ($183k), partially offset by increases in legal fees and salaries.
- One-Time Income: The company recognized $103,320 in "Other Income" from a settlement of a class-action lawsuit against its former auditor, BF Borgers CPA PC.
- Cash Burn: Net cash used in operating activities increased by $377k compared to the prior year, largely due to a $609k increase in accounts receivable.
Outlook, Risks, and Contingencies
- Liquidity: Management estimates current cash ($6.9M) plus operating cash flow will fund operations for approximately 17 months. No committed sources of capital exist, and future fundraising may be necessary.
- Legal Contingency: Following the termination of Nora Pharma President Mr. Malek Chamoun in April 2025, the company received a demand letter for approximately $5.3M USD. The company disputes the claim as unfounded and has made no accrual for this liability.
- Stock Split: Shareholders approved a potential reverse stock split of up to 1-for-10 in March 2026; the board retains discretion on execution.
- R&D Pipeline: Two proprietary candidates remain in animal testing: K1.1 mRNA (liver cancer) and SBFM-PL4 (SARS Coronavirus). A patent for the coronavirus protease inhibitor was issued in May 2026.
- Regulatory Risk: Revenue is highly dependent on Canadian government drug reimbursement policies and pricing negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA).
Investor Verification Checklist
- Legal Exposure: Verify the status of the $5.3M demand from the former subsidiary president and any potential impact on cash reserves.
- Revenue Sustainability: Assess the impact of the terminated distribution agreements on future quarterly sales and the timeline for launching the 22 drugs in the pipeline.
- Capital Needs: Confirm the 17-month runway estimate given the current quarterly burn rate of ~$1.2M and the lack of committed financing.
- Inventory Valuation: Review the $13.2M inventory balance and the $867k allowance for obsolescence, particularly given the reduction in active product lines.
- Reverse Split Execution: Monitor board announcements regarding the execution and ratio of the authorized reverse stock split.